Profile last edited on: 3/16/2021

   MTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Contact Information

16730 Calle De Catalina
Pacific Palisades, CA 90272
  (310) 309-9036

Public Profile

AADi, LLC, - also dba as AADI Biosciences - is a clinical stage biopharmaceutical company structured around in-house invented, lead product TARZIFYX™ - sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009 -- mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation and improved efficacy over other mTOR inhibitors in preclinical models. With mTOR as a therapeutic target well recognized in oncology, Aadi is focused on developing the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. These indications include oncology, cardiovascular, CNS, mitochondrial disease and diseases of ageing.
 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Investigation of a Nanoparticle Albumin-Bound Mtor Inhibitor, Nab-Rapamycin for T